Stocks · News reference
Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
US stock futures up, Dow futures gain 100+ points. Concentrix Corp (CNXC) shares down 24% after weak Q2 results and lowered FY26 guidance. Other stocks also decline in pre-market trading.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jun 30, 2026, 12:03 PM
- Checked
- Jun 30, 2026, 12:05 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Shares of crypto-linked stocks are trading higher as investors rotate into digital currencies as U.S. government spending concerns prompt debasement trade.
Read original at benzingaShares of crypto-linked companies are trading higher amid a rise in Bitcoin after President Trump urged Congress to pass the Clarity Act and said the Commodity Futures Trading Commission Chair Michael Selig is working to bring Hyperliquid to the U.S.
Read original at benzingaEric Trump Says It's 'Exciting to See' Bitcoin's Massive Surge, Deems Digital Assets as the 'Future'— ABTC Stock Rips 13%
Eric Trump, co-founder and Chief Strategy Officer of American Bitcoin Corp, expressed excitement over Bitcoin's dramatic surge on Wednesday, August 19.
Read original at benzingaAdlai Nortye H1 EPS $(0.04) Up From $(0.19) YoY, Sales $13.056M
Adlai Nortye (NASDAQ:ANL) reported quarterly losses of $(0.04) per share. This is a 78.95 percent increase over losses of $(0.19) per share from the same period last year. The company reported $13.056 million in sales
Read original at benzingaAdlai Nortye Submits Clinical Trial Notification To Australia's TGA And Receives Approval From HREC To Commence Phase I Clinical Trial Evaluating AN4035 For Treatment Of CEACAM5-Enriched RAS-Addicted Solid Tumors
First-in-class pan-RAS(ON) ADC is cleared for clinical developmentDesigned to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity.IND submissions to U.S. FDA and China NMPA are in
Read original at benzinga